Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer

NCT06827132

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Lung Cancer, Breast Cancer

Countries: Brazil, Egypt, Kenya

A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:Sample from adult patients (≥ 18 years) with suspected non-small cell lung cancer or invasive breast cancer or ductal carcinoma in situ.

\-

Exclusion Criteria:

* Samples with the inadequate technical quality of slides (pre-analytics quality) or images, e.g., broken slides, large out-of-focus areas, slides with fixation artefacts.

  * Samples from cases that were included in the training or technical validation.
  * Sample taken by fine needle aspiration.
  * Sample sent for cytological evaluation.
Locations (3)
  • São Paulo, Brazil
  • Giza, Egypt
  • Nairobi, Kenya